Product on VINCIT LifeSciences
Vincit LifeSciences offers world class products and services for various critical illness and diseases. At Vincit LifeSciences, our purpose is to improve the quality of life of the communities we serve.
The products that fall in the PPI range are as follows:
Rabeprozole is a antiulcer drug in the class of proton pump inhibitor. It is used in short term treatment in healing and symptomatic relief of duodenal ulcer and erosive or ulcerative gastroesophageal reflux diseases (GERD). It also used in long term treatment of pathological hypersecretory conditions including zollinger-ellision syndrome.

Mechanism of action
rabeprazole is selective irreversible ppi. Rabeprazole suppresses gastric acid secretion by specific inhibition of the hydrogen potassium adenosine triphosphate (H+, K+, ATpase) enzyme system found at the secretory surface of parietal cells. It inhibits the final transport of hydrogen ion (via exchange with potassium ions) into the gastric lumen. Since the H+ K+ ATPase enzyme system is regarded as the acid (proton) pump of gastric mucosa. Rabeprazole is known as a gastric acid pump inhibitor. Rabeprazole does not have anticholinergic or histamine H2 receptor antagonist properties.

It is medication specific blocker of dopamine receptor. It is administered orally. Domperidone is given in order to relieve nausea & vomiting. It increases the transit the food through the stomach and to increases lactation by release prolactin.

Mechanism of action
domperidon is a peripheral dopamine (D2 & D3) receptor antagonist. It provides relief from nausea by blocking receptors at the chemoreceptor trigger zone (location in nervous system that registers nausea). It blocks dopamine receptors in the posterior pituitary gland increasing release of prolactin which in turn increase lactation.

Pharmacokinetic Data
Rabeprazole sodium
Mostly non enzymatic partly Hepatic
Hepatic and Intestinal
Protein Binding
Half life
1 to 1.5 hrs
7 hrs
Renal 90%
Breast milk, Renal

  • Healing of duodenal ulcers
  • Gastric hyper-secretion
  • Gastro Esophageal reflux disease (GERD)
  • Heart burn symptoms

  • OD dose before meal.
  • Contains Rabeprazole sodium 20mg (Enteric coated) tab. Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.
    Acid is produced naturally in your stomach to help you digest food and to kill bacteria. This acid is irritant so your body produces a natural mucous barrier which protects the lining of your stomach. In some people, this barrier breaks down allowing the acid to damage the stomach, causing inflammation, ulcers and other conditions. In other people there may be a problem with the muscular band at the top of the stomach that keeps the stomach tightly closed. This may allow the acid to escape and irritate the oesophagus. This is called ‘acid reflux’ and can cause heartburn and/or oesophagitis.

    Proton pump inhibitors such as rabeprazole stop cells in the lining of the stomach from producing too much acid. This helps to prevent ulcers from forming, or assists the healing process where damage has already occurred. By decreasing the amount of acid, they can also help to reduce the symptoms of acid reflux disease, such as heartburn.

    Pharmacokinetic Data
    52 %
    Non-enzymatic, partly Hepatic
    Half Life
    1 to 1.5 hours
    90 % Renal
    • Gastric ulcers
    • Peptic ulsers
    • Hyperacidity/ Gastritis due to NSAIDs
    • Healing & Maintenance of Erosive or Ulcerative GERD
    • Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
    • Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
  • Just Once a day Rabevin-20 in GERD, duodenal, gastric, peptic ulcers. (Therapy for 4 weeks to 8 weeks)
  • In triple therapy for Helicobacter pylori infection , Rabevin-20 was combined with either clarithromycin 500 mg and metronidazole 400 mg, or amoxicillin 1000 mg and clarithromycin 500 mg, or amoxicillin 1000 mg and metronidazole 400 mg each given orally twice a day for 7 days. These combinations provided eradication rates of 100%, 95%, and 90% respectively.
  • In Zollinger-Ellison syndrome, * Initial: 60 mg orally once a day, after the morning meal, **Maintenance: Doses up to 100 mg orally once a day or 60 mg orally twice a day have been administered. Patients have been treated continuously for up to one year.